Qiagen NV has a consensus price target of $49.44 based on the ratings of 12 analysts. The high is $60 issued by Citigroup on February 8, 2024. The low is $42 issued by Baird on February 19, 2025. The 3 most-recent analyst ratings were released by Baird, UBS, and Morgan Stanley on February 19, 2025, February 7, 2025, and January 6, 2025, respectively. With an average price target of $46 between Baird, UBS, and Morgan Stanley, there's an implied 10.76% upside for Qiagen NV from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/04/2025 | Buy Now | — | Redburn Atlantic | Ed Ridley-Day13% | — | Downgrade | Buy → Neutral | Get Alert |
02/19/2025 | Buy Now | 1.13% | Baird | Catherine Schulte68% | $52 → $42 | Downgrade | Outperform → Neutral | Get Alert |
02/07/2025 | Buy Now | 15.58% | UBS | John Sourbeer30% | $50 → $48 | Maintains | Neutral | Get Alert |
01/06/2025 | Buy Now | 15.58% | Morgan Stanley | Steve Beuchaw65% | $51.5 → $49.44 | Downgrade | Overweight → Equal-Weight | Get Alert |
12/10/2024 | Buy Now | 30.03% | Jefferies | Tycho Peterson82% | $43.26 → $55.62 | Assumes | Hold → Buy | Get Alert |
10/17/2024 | Buy Now | — | HSBC | Shubhangi Gupta7% | — | Downgrade | Buy → Hold | Get Alert |
08/02/2024 | Buy Now | 25.21% | Baird | Catherine Schulte68% | $50.47 → $53.56 | Maintains | Outperform | Get Alert |
06/27/2024 | Buy Now | 20.39% | Wolfe Research | Doug Schenkel71% | → $51.5 | Upgrade | Peer Perform → Outperform | Get Alert |
06/18/2024 | Buy Now | 30.03% | JP Morgan | Casey Woodring28% | $53.56 → $55.62 | Maintains | Overweight | Get Alert |
05/01/2024 | Buy Now | 8.36% | Stifel | Daniel Arias78% | $56.65 → $46.35 | Maintains | Hold | Get Alert |
02/16/2024 | Buy Now | 22.8% | Morgan Stanley | Steve Beuchaw65% | $50.96 → $52.53 | Upgrade | Equal-Weight → Overweight | Get Alert |
02/08/2024 | Buy Now | 25.21% | JP Morgan | Casey Woodring28% | $51.5 → $53.56 | Maintains | Overweight | Get Alert |
02/08/2024 | Buy Now | 44.47% | Citigroup | Patrick Donnelly80% | $63.72 → $61.8 | Maintains | Buy | Get Alert |
12/20/2023 | Buy Now | 20.39% | JP Morgan | Casey Woodring28% | $47.74 → $53.05 | Maintains | Overweight | Get Alert |
12/19/2023 | Buy Now | 5.95% | Wells Fargo | Timothy Daley56% | → $46.68 | Initiates | → Equal-Weight | Get Alert |
12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel71% | — | Initiates | → Peer Perform | Get Alert |
12/07/2023 | Buy Now | — | Goldman Sachs | Matthew Sykes65% | — | Upgrade | Neutral → Buy | Get Alert |
11/02/2023 | Buy Now | 1.13% | UBS | John Sourbeer30% | $50.92 → $44.56 | Maintains | Neutral | Get Alert |
10/17/2023 | Buy Now | 20.39% | JP Morgan | Casey Woodring28% | $58.35 → $53.05 | Maintains | Overweight | Get Alert |
09/26/2023 | Buy Now | 44.47% | Citigroup | Patrick Donnelly80% | $63.65 → $63.65 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | Buy Now | 20.39% | Baird | Catherine Schulte68% | → $53.05 | Initiates | → Outperform | Get Alert |
08/09/2023 | Buy Now | 15.58% | UBS | John Sourbeer30% | $53.05 → $50.92 | Maintains | Neutral | Get Alert |
02/09/2023 | Buy Now | 25.21% | UBS | John Sourbeer30% | $53.05 → $55.17 | Maintains | Neutral | Get Alert |
02/09/2023 | Buy Now | 44.47% | Citigroup | Patrick Donnelly80% | $58.35 → $63.65 | Maintains | Buy | Get Alert |
11/09/2022 | Buy Now | 32.43% | Citigroup | Patrick Donnelly80% | $65.78 → $58.35 | Maintains | Buy | Get Alert |
The latest price target for Qiagen (NYSE:QGEN) was reported by Redburn Atlantic on April 4, 2025. The analyst firm set a price target for $0.00 expecting QGEN to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Qiagen (NYSE:QGEN) was provided by Redburn Atlantic, and Qiagen downgraded their neutral rating.
The last upgrade for Qiagen NV happened on June 27, 2024 when Wolfe Research raised their price target to $50. Wolfe Research previously had a peer perform for Qiagen NV.
The last downgrade for Qiagen NV happened on April 4, 2025 when Redburn Atlantic changed their price target from N/A to N/A for Qiagen NV.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Qiagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Qiagen was filed on April 4, 2025 so you should expect the next rating to be made available sometime around April 4, 2026.
While ratings are subjective and will change, the latest Qiagen (QGEN) rating was a downgraded with a price target of $0.00 to $0.00. The current price Qiagen (QGEN) is trading at is $41.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.